Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellares and TScan to assess automated manufacturing of TSC-101 therapy
With the agreement, TCR-engineered T cell therapies such as TSC-101 become part of Cellares’ automated platform portfolio. Credit: PeopleImages / Shutterstock.com.
With the agreement, TCR-engineered T cell therapies such as TSC-101 become part of Cellares’ automated platform portfolio. Credit: PeopleImages / Shutterstock.com.